Study demonstrated clear target engagement at both tested doses Potential for THRV-1268 to address prolonged QTcF in cardiometabolic diseases Phase 2a ASPIRE-HF study to commence enrollment in 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback